Valeo Financial Advisors LLC Acquires 51 Shares of Cencora, Inc. (NYSE:COR)

Valeo Financial Advisors LLC lifted its position in shares of Cencora, Inc. (NYSE:COR) by 3.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,566 shares of the company’s stock after buying an additional 51 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Cencora were worth $353,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Rise Advisors LLC purchased a new stake in shares of Cencora during the 1st quarter worth $25,000. Legacy Bridge LLC purchased a new stake in shares of Cencora during the 1st quarter worth $27,000. TCTC Holdings LLC purchased a new stake in shares of Cencora during the 1st quarter worth $29,000. TFO Wealth Partners LLC purchased a new stake in shares of Cencora during the 1st quarter worth $30,000. Finally, LRI Investments LLC purchased a new stake in shares of Cencora during the 1st quarter worth $31,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The disclosure for this sale can be found here. Insiders have sold 6,338,756 shares of company stock worth $1,476,658,274 over the last quarter. 15.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. SVB Leerink reiterated an “outperform” rating and issued a $275.00 price target on shares of Cencora in a research note on Thursday, June 27th. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Wells Fargo & Company raised their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Citigroup raised their target price on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Finally, Robert W. Baird raised their price objective on Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $254.57.

Cencora Price Performance

COR traded down $4.10 during trading on Thursday, hitting $237.00. The company’s stock had a trading volume of 1,747,211 shares, compared to its average volume of 1,396,692. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.93. The business’s fifty day simple moving average is $230.21 and its 200 day simple moving average is $231.72. The firm has a market capitalization of $47.27 billion, a price-to-earnings ratio of 25.93, a P/E/G ratio of 1.68 and a beta of 0.45. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $247.66.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same period in the previous year, the company posted $2.92 earnings per share. The business’s revenue was up 10.8% on a year-over-year basis. On average, equities research analysts forecast that Cencora, Inc. will post 13.56 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 26th. Shareholders of record on Friday, August 9th will be given a $0.51 dividend. The ex-dividend date of this dividend is Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.86%. Cencora’s dividend payout ratio is currently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.